Parkinson
67
10
11
29
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
1.5%
1 terminated out of 67 trials
96.7%
+10.2% vs benchmark
6%
4 trials in Phase 3/4
17%
5 of 29 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 29 completed trials
Clinical Trials (67)
Studies of Brain and Body Interaction
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
The Brain&Senses Study
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
Optimistic and Pessimistic Dopamine Signals in the Human Brain: a Mapping and Modelling Study in Health and Parkinson's Disease
Colonic Tissue Biopsy Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis or REM Sleep Behavior Disorder
Comparing Biomarker-Guided DBS Programming With Standard Clinical Monopolar Programming
Effects of Otago and Frenkel's Exercises on Strengthening of Antigravity Muscles in Parkinson's Disease.
Effects of Transcranial Pulse Stimulation in Parkinson's Disease
Transforming Parkinson's Care With Predictive Algorithms
Study of Gastrointestinal Dysfunction and Enteric Neural Pathology in Patients With Parkinson's Disease
Which Tools Better Predict Fall Risk in Parkinson's Disease: A Comparative Study of Objective, Self-Reported, and Functional Balance Assessment
Neuroplasticity in Parkinson's Disease
Mediterranean Diet Effects on Parkinson's Disease
Clinical Investigation of NMS Assist
Neurologic Stem Cell Treatment Study
A Pilot Comparative Bioavailability Study of Levodopa Administered Via Levodopa Cyclops® Relative to INBRIJA®
Impact of Ketoflex 12/3 Diet on Parkinson's Disease Symptoms: A Clinical Study
Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers
Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)